DBV Technologies (DBV) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Strategic and clinical program updates

• Two BLAs planned: one for children aged 4–7 by mid-2026, and one for ages 1–3 by end of 2026, both for Viaskin Peanut targeting peanut allergy in children.

• Viaskin Peanut has FDA breakthrough designation and will seek priority review for the first filing.

• VITESSE trial, the largest in peanut allergy, showed a 32-point placebo-adjusted efficacy delta and strong safety profile in 654 patients aged 4–7.

• Efficacy in 1–3 year-olds was consistent, with a 67% response rate at year one, rising to 86% at year three; 68% could tolerate a full food challenge after three years.

• BLAs are supported by extensive open-label extension data, showing improved efficacy and safety over time.

Market opportunity and commercial strategy

• U.S. market includes 390,000 children aged 4–7 and 280,000 aged 1–3 with peanut allergy, totaling 670,000 children.

• Target prescriber base is 4,500 allergists; 60% of children with peanut allergy are already seen by allergists.

• Commercial launch expected in first half of 2027, with a sales force of 50–70 reps and strong engagement with advocacy groups and families.

• Pricing reference is Palforzia at $1,000/month, with potential for a premium based on product differentiation.

• Manufacturing capacity is sufficient for initial launch, with plans to triple capacity for future growth and ex-U.S. expansion.

Competitive landscape and product differentiation

• Viaskin Peanut offers a patch-based, disease-modifying therapy, contrasting with IgE blockade (e.g., Xolair) and oral immunotherapy (Palforzia).

• Patch therapy is seen as safer and more convenient, with no severe anaphylaxis observed and no REMS anticipated.

• Palforzia requires frequent dose escalation visits and has higher rates of anaphylaxis, making Viaskin's patch more attractive to families and physicians.

• Peanut allergy is the top concern for parents due to its ubiquity and unpredictability, even among children with multiple food allergies.

• IgE blockade is not widely used in young children due to safety concerns and administration challenges.